Literature DB >> 16015385

Fusion of NUP214 to ABL1 on amplified episomes in T-ALL--implications for treatment.

K Stergianou, C Fox, N H Russell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16015385     DOI： 10.1038/sj.leu.2403877

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

1.  Characterization of KRAS rearrangements in metastatic prostate cancer.

Authors:  Xiao-Song Wang; Sunita Shankar; Saravana M Dhanasekaran; Bushra Ateeq; Atsuo T Sasaki; Xiaojun Jing; Daniel Robinson; Qi Cao; John R Prensner; Anastasia K Yocum; Rui Wang; Daniel F Fries; Bo Han; Irfan A Asangani; Xuhong Cao; Yong Li; Gilbert S Omenn; Dorothee Pflueger; Anuradha Gopalan; Victor E Reuter; Emily Rose Kahoud; Lewis C Cantley; Mark A Rubin; Nallasivam Palanisamy; Sooryanarayana Varambally; Arul M Chinnaiyan
Journal:  Cancer Discov       Date:  2011-06-01       Impact factor: 39.397

2.  NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors.

Authors:  Nicolas Duployez; Guillaume Grzych; Benoît Ducourneau; Martin Alarcon Fuentes; Nathalie Grardel; Thomas Boyer; Wadih Abou Chahla; Bénédicte Bruno; Brigitte Nelken; Emmanuelle Clappier; Claude Preudhomme
Journal:  Haematologica       Date:  2015-12-17       Impact factor: 9.941

3.  Molecular monitoring in NUP214-ABL-positive T-acute lymphoblastic leukemia reveals clonal diversity and helps to guide targeted therapy.

Authors:  S Koschmieder; T Burmeister; M Brüggemann; A Berkemeier; S Volpert; P Wieacker; G Silling; N Gökbuget; C Müller-Tidow; W E Berdel; M Stelljes
Journal:  Leukemia       Date:  2013-09-19       Impact factor: 11.528

Review 4.  Cell-Free eccDNAs: A New Type of Nucleic Acid Component for Liquid Biopsy?

Authors:  Jing Zhu; Siyu Chen; Fan Zhang; Liang Wang
Journal:  Mol Diagn Ther       Date:  2018-10       Impact factor: 4.074

5.  Unique amplification of BCR-ABL1 gene fusion in a case of T-cell acute lymphoblastic leukemia.

Authors:  Rima Koka; Najeebah A Bade; Edward A Sausville; Yi Ning; Ying Zou
Journal:  Mol Cytogenet       Date:  2017-10-26       Impact factor: 2.009

6.  Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214::ABL1 Gene Fusion.

Authors:  Egle Stukaite-Ruibiene; Rimvydas Norvilas; Vaidas Dirse; Sigita Stankeviciene; Goda Elizabeta Vaitkeviciene
Journal:  Pathol Oncol Res       Date:  2022-09-12       Impact factor: 2.874

7.  Case Report: The First Report of NUP214-ABL1 Fusion Gene in Acute Myeloid Leukemia Patient Detected by Next-Generation Sequencing.

Authors:  Huan-Ping Wang; Jun-Jun He; Qiao-Yun Zhu; Lin Wang; Jian-Hu Li; Jian-Song Huang; Wan-Zhuo Xie; Hong-Hu Zhu; Jie Jin
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

8.  Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia.

Authors:  Marlies Vanden Bempt; Sofie Demeyer; Michaël Broux; Jolien De Bie; Simon Bornschein; Nicole Mentens; Roel Vandepoel; Ellen Geerdens; Enrico Radaelli; Beat C Bornhauser; Andreas E Kulozik; Jules P Meijerink; Jean-Pierre Bourquin; Charles E de Bock; Jan Cools
Journal:  Cancer Cell       Date:  2018-08-13       Impact factor: 31.743
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.